MAP2K7 and non-small cell lung carcinoma: Effect of combination treatment with trametinib and vemurafenib. Treatment with combination of MEK inhibitor and BRAF inhibitor has been effective in advanced melanoma with BRAF-V600 mutation but the effect of MEK inhibitor or this similar combination has not been explored in BRAF mutated NSCLC [12].